Related Experiment Video
Updated: Apr 12, 2026

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
Published on: April 4, 2018
Systematic Validation of RNF213 Coding Variants in Japanese Patients With Moyamoya Disease
Yosuke Moteki1, Hideaki Onda1, Hidetoshi Kasuya2
1Department of Neurosurgery, Neurological Institute, Tokyo Women's Medical University, Tokyo, Japan (Y.M., H.O., T.Y., Y.O.).
Background:
A founder variant of RNF213, p.R4810K (c.14429G>A, rs112735431), was recently identified as a major genetic risk factor for moyamoya disease (MMD) in Japan. Although the association of p.R4810K was reported to be highly significant and reproducible, the disease susceptibility of other RNF213 variants remains largely unknown. In the present study, we systematically evaluated the coding variants detected in Japanese patients and controls for associations with MMD.
Methods And Results:
To detect variants of RNF213, all coding exons were sequenced in 27 Japanese MMD patients without p.R4810K. We also validated all previously reported variants in our case-control samples and tested for associations in combination with previous Japanese study cohorts, including the 1000 Genomes Project data set, as population-based controls. Forty-six missense variants other than p.R4810K were identified among 370 combined patients and 279 combined controls in Japan. Sixteen of 46 variants were polymorphisms with minor allele frequency >1%, and, after conditioning on the p.R4810K genotype, were not associated with MMD. We conducted a variable threshold test using Combined Annotation-Dependent Depletion on the remaining 30 rare variants (minor allele frequency <1%), and the results showed that the frequency of potentially functional variants was significantly higher in patients than in controls (permutation, minimum P=0.045).
Conclusions:
Not only p.4810K but also other functional missense variants of RNF213 conferred susceptibility to MMD. Our analysis also revealed that ≈20% of Japanese MMD patients did not harbor susceptibility variants of RNF213, indicating the presence of other susceptibility genes for MMD.
Insights
Other RNF213 gene variants, besides the known p.R4810K, increase the risk for moyamoya disease (MMD). However, some MMD patients lack these RNF213 variants, suggesting other genes are involved.
Area of Science:
- Genetics
- Neurology
- Rare Diseases
Background:
- Moyamoya disease (MMD) is a rare cerebrovascular disorder.
- A specific RNF213 variant, p.R4810K, is a known risk factor for MMD in Japan.
- The role of other RNF213 variants in MMD susceptibility is largely unknown.
Purpose of the Study:
- To systematically evaluate the association of RNF213 coding variants with MMD in the Japanese population.
- To identify novel genetic risk factors for MMD beyond the p.R4810K variant.
Main Methods:
- Sequencing of RNF213 coding exons in MMD patients.
- Case-control association study combining patient cohorts and population data.
- Statistical analysis including variable threshold testing and Combined Annotation-Dependent Depletion (CADe) for rare variants.
Main Results:
- Forty-six missense variants in RNF213, excluding p.R4810K, were identified.
- Sixteen common variants (MAF >1%) showed no association with MMD.
- Thirty rare variants (MAF <1%) demonstrated a significantly higher frequency in MMD patients, indicating potential functional roles.
Conclusions:
- Functional missense variants in RNF213, in addition to p.R4810K, contribute to MMD susceptibility.
- Approximately 20% of Japanese MMD patients do not carry known RNF213 susceptibility variants, highlighting the need to explore other genetic factors.
Related Concept Videos
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Mitral Stenosis II: Clinical features and Diagnostic Tests
Rheumatic Heart Disease I: Introduction
Translation
Translation Produces the Building Blocks of Life
Proteins are...
Principles of Pharmacogenetics: Types of Genetic Variants
Single Nucleotide Polymorphisms-SNPs

